{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:27:55Z","timestamp":1787016475564,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1124\/jpet.121.000994","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T08:30:14Z","timestamp":1646296214000},"page":"188-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Therapeutic Basis of Generic Substitution of Antiseizure Medications"],"prefix":"10.1016","volume":"381","author":[{"given":"Sarah","family":"Elmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doodipala Samba","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1124\/jpet.121.000994_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s40258-014-0146-1","article-title":"Definition and classification of generic drugs across the world","volume":"13","author":"Alfonso-Cristancho","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1124\/jpet.121.000994_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-009-0066-3","article-title":"Seizure risk in brain tumor patients with conversion to generic levetiracetam","volume":"98","author":"Armstrong","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1124\/jpet.121.000994_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40064-016-1824-2","article-title":"Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature","volume":"5","author":"Atif","year":"2016","journal-title":"Springerplus"},{"key":"10.1124\/jpet.121.000994_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.yebeh.2008.06.001","article-title":"Generic substitution in the treatment of epilepsy: patient and physician perceptions","volume":"13","author":"Berg","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1124\/jpet.121.000994_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"key":"10.1124\/jpet.121.000994_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jamaneurol.2017.0497","article-title":"Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial","volume":"74","author":"Berg","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1124\/jpet.121.000994_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4321\/S1886-36552010000100006","article-title":"Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients","volume":"8","author":"Blix","year":"2010","journal-title":"Pharm Pract (Granada)"},{"key":"10.1124\/jpet.121.000994_bib8","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","article-title":"The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs","volume":"25","author":"Borgheini","year":"2003","journal-title":"Clin Ther"},{"key":"10.1124\/jpet.121.000994_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.121.000994_bib10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1528-1167.2011.03025.x","article-title":"Clinical experience with generic levetiracetam in people with epilepsy","volume":"52","author":"Chaluvadi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000994_bib11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1023\/A:1013319408893","article-title":"Bioavailability and bioequivalence: an FDA regulatory overview","volume":"18","author":"Chen","year":"2001","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.121.000994_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1528-1157.1982.tb05062.x","article-title":"Comparative bioavailability of phenytoin from generic formulations in the United Kingdom","volume":"23","author":"Chen","year":"1982","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000994_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/wics.1310","article-title":"Bioavailability and bioequivalence in drug development","volume":"6","author":"Chow","year":"2014","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"key":"10.1124\/jpet.121.000994_bib14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1M141","article-title":"Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration","volume":"43","author":"Davit","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1124\/jpet.121.000994_bib15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","article-title":"Switching from brand-name to generic psychotropic medications: a literature review","volume":"17","author":"Desmarais","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1124\/jpet.121.000994_bib16","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1212\/WNL.0b013e3181aa5300","article-title":"The risks and costs of multiple-generic substitution of topiramate","volume":"72","author":"Duh","year":"2009","journal-title":"Neurology"},{"key":"10.1124\/jpet.121.000994_bib17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(06)68477-8","article-title":"Adult epilepsy","volume":"367","author":"Duncan","year":"2006","journal-title":"Lancet"},{"key":"10.1124\/jpet.121.000994_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-14-1","article-title":"A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study","volume":"14","author":"Dunne","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1124\/jpet.121.000994_bib19","unstructured":"Epilepsy Foundation Medication Switching Position Statement. (2006). https:\/\/www.epilepsy.com\/sites\/core\/files\/atoms\/files\/Medication%20Switching%20Position%20Statement.pdf"},{"key":"10.1124\/jpet.121.000994_bib20","unstructured":"FDA Approved Drug Products. (2021). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"10.1124\/jpet.121.000994_bib21","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1345\/aph.1P765","article-title":"Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures","volume":"45","author":"Fitzgerald","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1124\/jpet.121.000994_bib22","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.3390\/pharmacy6020043","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice","volume":"6","author":"Fuentes","year":"2018","journal-title":"Pharmacy (Basel)"},{"key":"10.1124\/jpet.121.000994_bib23","first-page":"392","article-title":"Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment","volume":"35","author":"Goldenberg","year":"2010","journal-title":"P T"},{"key":"10.1124\/jpet.121.000994_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.298.1.61","article-title":"Prescription drug cost sharing: associations with medication and medical utilization and spending and health","volume":"298","author":"Goldman","year":"2007","journal-title":"JAMA"},{"key":"10.1124\/jpet.121.000994_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.121.000994_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0317167100051957","article-title":"Generic substitution for brand name antiepileptic drugs: a survey","volume":"27","author":"Guberman","year":"2000","journal-title":"Can J Neurol Sci"},{"key":"10.1124\/jpet.121.000994_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.2042-7158.1991.tb06644.x","article-title":"Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy","volume":"43","author":"Hartley","year":"1991","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.121.000994_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1742-1241.1990.tb10813.x","article-title":"Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?","volume":"44","author":"Hartley","year":"1990","journal-title":"Br J Clin Pract"},{"key":"10.1124\/jpet.121.000994_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(07)70105-9","article-title":"Antiepileptic drugs: generic versus branded treatments","volume":"6","author":"Heaney","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.121.000994_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.sapharm.2019.01.013","article-title":"Communicating benefits and risks of generic drugs to consumers: patient and caregiver opinions of two FDA-developed educational materials","volume":"15","author":"Hohmann","year":"2019","journal-title":"Res Social Adm Pharm"},{"key":"10.1124\/jpet.121.000994_bib31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/epi.14439","article-title":"Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?","volume":"59","author":"Holtkamp","year":"2018","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000994_bib32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/009885881203800403","article-title":"Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs","volume":"38","author":"Hottinger","year":"2012","journal-title":"Am J Law Med"},{"key":"10.1124\/jpet.121.000994_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/014107689308600305","article-title":"Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example","volume":"86","author":"Jain","year":"1993","journal-title":"J R Soc Med"},{"key":"10.1124\/jpet.121.000994_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/17425255.2015.989211","article-title":"Is bioavailability altered in generic versus brand anticonvulsants?","volume":"11","author":"Jankovic","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/jpet.121.000994_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ewjm.175.2.99","article-title":"Seizure disorders: part 1. classification and diagnosis","volume":"175","author":"Kammerman","year":"2001","journal-title":"West J Med"},{"key":"10.1124\/jpet.121.000994_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ejps.2013.08.023","article-title":"Quantitative assessment of the switchability of generic products","volume":"50","author":"Karalis","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/jpet.121.000994_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40263-013-0112-8","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations","volume":"28","author":"Karalis","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1124\/jpet.121.000994_bib38","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1377\/hlthaff.25.6.1637","article-title":"Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending","volume":"25","author":"Kesselheim","year":"2006","journal-title":"Health Aff (Millwood)"},{"key":"10.1124\/jpet.121.000994_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/2013.jamainternmed.997","article-title":"Variations in pill appearance of antiepileptic drugs and the risk of nonadherence","volume":"173","author":"Kesselheim","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1124\/jpet.121.000994_bib40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/10898530-000000000-00000","article-title":"Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis","volume":"70","author":"Kesselheim","year":"2010","journal-title":"Drugs"},{"key":"10.1124\/jpet.121.000994_bib41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archneur.1987.00520180004003","article-title":"Untoward effects of generic carbamazepine therapy","volume":"44","author":"Koch","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.121.000994_bib42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.tins.2015.10.002","article-title":"Controlling cerebellar output to treat refractory epilepsy","volume":"38","author":"Kros","year":"2015","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.121.000994_bib43","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/jnnp.2004.045690","article-title":"The natural history of epilepsy: an epidemiological view","volume":"75","author":"Kwan","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.121.000994_bib44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4088\/JCP.v61n0914h","article-title":"Side effect profile of enteric-coated divalproex sodium versus valproic acid","volume":"61","author":"Levine","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.121.000994_bib45","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.1978.03290200068031","article-title":"Valproic acid (Depakene). A new anticonvulsant agent","volume":"240","author":"Lewis","year":"1978","journal-title":"JAMA"},{"key":"10.1124\/jpet.121.000994_bib46","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1212\/01.wnl.0000259400.30539.cc","article-title":"Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy","volume":"68","author":"Liow","year":"2007","journal-title":"Neurology"},{"key":"10.1124\/jpet.121.000994_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108055","article-title":"The feast and famine: epilepsy treatment and treatment gaps in early 21st century","volume":"170","author":"L\u00f6scher","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.121.000994_bib48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clinthera.2007.02.005","article-title":"Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy","volume":"29","author":"Makus","year":"2007","journal-title":"Clin Ther"},{"key":"10.1124\/jpet.121.000994_bib49","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1023\/A:1015872626887","article-title":"The bioinequivalence of carbamazepine tablets with a history of clinical failures","volume":"9","author":"Meyer","year":"1992","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.121.000994_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yebeh.2008.02.020","article-title":"Comparative daily profiles with different preparations of lamotrigine: a pilot investigation","volume":"13","author":"Nielsen","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1124\/jpet.121.000994_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/epi.16802","article-title":"Bioequivalence and switchability of generic antiseizure medications (ASMs): a re-appraisal based on analysis of generic ASM products approved in Europe","volume":"62","author":"Odi","year":"2021","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000994_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.clinthera.2009.02.001","article-title":"Bioequivalence of single 100-mg doses of two oral formulations of topiramate: an open-label, randomized-sequence, two-period crossover study in healthy adult male Mexican volunteers","volume":"31","author":"Pi\u00f1eyro-L\u00f3pez","year":"2009","journal-title":"Clin Ther"},{"key":"10.1124\/jpet.121.000994_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.121.000994_bib54","first-page":"209","article-title":"Bioequivalence: an overview of statistical concepts","volume":"36","author":"Rani","year":"2004","journal-title":"Indian J Pharmacol"},{"key":"10.1124\/jpet.121.000994_bib55","first-page":"5165","article-title":"Clinical Pharmacology and Therapeutics of Antiepileptic Drugs for Treatment of Epilepsy and Seizure Disorders","volume":"13","author":"Reddy","year":"2020","journal-title":"Int. J. Pharm. Sci. Nanotech"},{"key":"10.1124\/jpet.121.000994_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.000994_bib57","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1528-1157.1994.tb02487.x","article-title":"Comparative bioavailability of a generic phenytoin and Dilantin","volume":"35","author":"Rosenbaum","year":"1994","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000994_bib58","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(87)90619-2","article-title":"Generic versus branded carbamazepine","volume":"1","author":"Sachdeo","year":"1987","journal-title":"Lancet"},{"key":"10.1124\/jpet.121.000994_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00019052-200304000-00008","article-title":"The epidemiology of epilepsy revisited","volume":"16","author":"Sander","year":"2003","journal-title":"Curr Opin Neurol"},{"key":"10.1124\/jpet.121.000994_bib60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1017\/S1092852900027358","article-title":"Understanding therapeutic equivalence in epilepsy","volume":"15","author":"Sankar","year":"2010","journal-title":"CNS Spectr"},{"key":"10.1124\/jpet.121.000994_bib61","first-page":"81","article-title":"The controversy over generic antiepileptic drugs","volume":"15","author":"Shaw","year":"2010","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1124\/jpet.121.000994_bib62","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.5414\/CP202153","article-title":"Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations","volume":"52","author":"Shin","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/jpet.121.000994_bib63","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archinte.166.3.332","article-title":"The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions","volume":"166","author":"Shrank","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.121.000994_bib64","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/jnnp.55.8.688","article-title":"Bioavailability and dissolution of proprietary and generic formulations of phenytoin","volume":"55","author":"Soryal","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.121.000994_bib66","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide","volume":"71","author":"Tamargo","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.121.000994_bib67","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13095","article-title":"Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard","volume":"56","author":"Ting","year":"2015","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000994_bib68","first-page":"481","article-title":"[Generic carbamazepine-induced subacute adrenal insufficiency?]","volume":"153","author":"Vergely","year":"2002","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1124\/jpet.121.000994_bib69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5698\/1535-7511-16.3.209","article-title":"AES position statement on generic substitution of antiepileptic drugs","volume":"16","author":"Vossler","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1124\/jpet.121.000994_bib70","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/106002809202600605","article-title":"Loss of seizure control associated with generic substitution of carbamazepine","volume":"26","author":"Welty","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1124\/jpet.121.000994_bib71","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.yebeh.2004.05.011","article-title":"Therapeutic equivalency of generic antiepileptic drugs: results of a survey","volume":"5","author":"Wilner","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1124\/jpet.121.000994_bib72","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1345\/aph.1Q349","article-title":"Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies","volume":"45","author":"Yamada","year":"2011","journal-title":"Ann Pharmacother"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:18:11Z","timestamp":1739953091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524002623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0022356524002623"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000994","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Basis of Generic Substitution of Antiseizure Medications","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}